J.P. Morgan Trends: Digital Health Confusion, Tech, Drug Prices and Diversity

As the JP Morgan Healthcare Conference enters its final day for 2020, a few topics have risen to the top as trending. One, of course, has been the relative lack of big deals. At least one analyst, Joseph Schimmer with Evercore ISI, believes its related to it being an election year. In a note to clients prior to JPM he noted that January is typically the busiest month for M&A in biotech, but the last big slow year was January 2016.